fbpx
QQQ
-1.91
368.39
-0.52%
DIA
-1.32
352.14
-0.38%
SPY
-2.11
442.76
-0.48%
TLT
+ 0.70
148.12
+ 0.47%
GLD
-1.36
172.53
-0.79%

BofA Sees Blockbuster Sales Potential For GW Pharma's CBD Drug Epidiolex

February 4, 2020 12:02 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
BofA Sees Blockbuster Sales Potential For GW Pharma's CBD Drug Epidiolex

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), which derives a lion's share of its revenues from its cannabinoid seizure drug Epidiolex, provides value for investors due to the potential for the drug to have wide utility over both orphan and non-orphan indications, according to BofA Securities.

The GW Pharma Analyst

Tazeen Ahmad maintained a Buy rating on GW Pharma with a $224 price target.

The GW Pharma Thesis

The update came after a teleconference call with an epilepsy specialist who treats about 260 patients, Ahmad said in a Tuesday note. (See her track record here.)

Out of 45 patients on Epidiolex, four to five patients have dropped off the treatment, translating to a 10% discontinuation rate, the analyst said.

The discontinuations had more to do with parental requests or adverse events, including diarrhea and liver enzyme elevations, rather than to a lack of efficacy, she said.

The specialist indicated that about 40-50% of patients were well-controlled on a dose regimen of 10mg/kg twice daily, although for non-responders, a dose above 20mg/kg was administered, Ahmad said.

The doctor reported comparable or slightly higher response rates compared to published data, according to BofA. About one-third of the patients showed improvement in sleep, adding to their quality of life. 

The doctor suggested that out of the 10 tuberous sclerosis complex patients he follows, he is likely to treat three to five with Epidiolex after the sNDA for an expanded labeling to use it for TSC is approved, the analyst said.

GW Pharma announced Monday it has submitted the sNDA for TSC.

BofA estimates Epidiolex risk-adjusted peak sales of $2.5 billion in 2027 across Dravet syndrome, Lennox-Gastaut syndrome, TSC and off-label indications.

GW Pharma Price Action

The stock was trading 2.5% higher at $118.36 at the time of publication Tuesday.

Related Links:

The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes

Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

Photo courtesy of GW Pharma.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

PreMarket Prep Stock Of The Day: GW Pharmaceuticals

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session. read more

7 High-Risk Stocks For Market Gamblers

Casinos are just starting to open back up following COVID-19 shutdowns, but it may still be a while before some gamblers are willing to venture back to Vegas or even their local casino. Sports gamblers are still waiting for the return of Major League Baseball and other pro and college sports leagues. read more

GW Pharma's Epidiolex Label Expansion, EU Launch Key Growth Drivers In 2020

GW Pharma Analyst Expects $475M In Sales Of CBD Drug Expidiolex This Year